Differentiated strategy has potential to create greater and greater value

Announcing the BioCryst Pharmaceuticals, Inc. financial results for the first quarter ended 31 March 2021, President and CEO Jon Stonehouse says:

“Our commercial team is off to an outstanding start with the U.S. launch of Orladeyo. In this highly competitive market, we are demonstrating what we have known for some time now, HAE patients have been waiting to switch to an oral, once-daily therapy to reduce their attacks and burden of therapy. Our early launch performance is the latest piece of evidence that our differentiated strategy to discover, develop and, now, successfully commercialize unique oral medicines for rare diseases has the potential to create greater and greater value.”

The majority of the Orladeyo revenue in the first quarter of 2021 came from new patients who switched to Orladeyo from either injectable/infused prophylactic medications or from acute-only treatment. The remainder came from patients transitioning from clinical trials and the company’s early access program.
(Source: BioCryst)